We stopped the pharmaceutical company Indivior from using misleading marketing to promote Opvee, an opioid overdose drug that's unauthorized in New York.
Indivior wrongly promoted Opvee as an alternative to Narcan to officials.
I'll always fight to combat the opioid crisis.
Indivior wrongly promoted Opvee as an alternative to Narcan to officials.
I'll always fight to combat the opioid crisis.
September 30, 2025 at 2:52 PM
We stopped the pharmaceutical company Indivior from using misleading marketing to promote Opvee, an opioid overdose drug that's unauthorized in New York.
Indivior wrongly promoted Opvee as an alternative to Narcan to officials.
I'll always fight to combat the opioid crisis.
Indivior wrongly promoted Opvee as an alternative to Narcan to officials.
I'll always fight to combat the opioid crisis.
AAAAHAHAHAHAHAHAHAHAAAAAA
HELL YEAH
HELL YEAH
September 5, 2025 at 11:31 PM
AAAAHAHAHAHAHAHAHAHAAAAAA
HELL YEAH
HELL YEAH
"Drug maker Indivior joins London Stock Exchange exodus"
Another big firm delisting from Londons' FTSE is a major blow to the CoL already reeling from brexit. No amount of cherry picking will fix this.
EU Single Market Freedom of Movement includes: Goods, Services, People & Capital.
🧵
Another big firm delisting from Londons' FTSE is a major blow to the CoL already reeling from brexit. No amount of cherry picking will fix this.
EU Single Market Freedom of Movement includes: Goods, Services, People & Capital.
🧵
June 2, 2025 at 6:37 PM
"Drug maker Indivior joins London Stock Exchange exodus"
Another big firm delisting from Londons' FTSE is a major blow to the CoL already reeling from brexit. No amount of cherry picking will fix this.
EU Single Market Freedom of Movement includes: Goods, Services, People & Capital.
🧵
Another big firm delisting from Londons' FTSE is a major blow to the CoL already reeling from brexit. No amount of cherry picking will fix this.
EU Single Market Freedom of Movement includes: Goods, Services, People & Capital.
🧵
Indivior to stop marketing Opvee, controversial overdose-reversal medication
"a significant win for the harm reduction community"
www.statnews.com/2025/09/30/n...
"a significant win for the harm reduction community"
www.statnews.com/2025/09/30/n...
Indivior to stop marketing Opvee, controversial overdose-reversal medication
Indivior is halting Opvee promotion after a New York settlement. Critics say the overdose drug is overpriced, risky, and no safer than widely used naloxone.
www.statnews.com
September 30, 2025 at 6:10 PM
Indivior to stop marketing Opvee, controversial overdose-reversal medication
"a significant win for the harm reduction community"
www.statnews.com/2025/09/30/n...
"a significant win for the harm reduction community"
www.statnews.com/2025/09/30/n...
Seems like the author glossed over any conflict of interest from Humphreys being on the board of directors of Indivior, one of the most scandal ridden opiate manufacturers
June 16, 2025 at 3:13 PM
Seems like the author glossed over any conflict of interest from Humphreys being on the board of directors of Indivior, one of the most scandal ridden opiate manufacturers
Humphreys is a Director of Indivior, the company that makes sublocade
ca.investing.com/news/insider...
ca.investing.com/news/insider...
Humphreys Keith buys Indivior (INDV) shares worth $27,429 By Investing.com
Humphreys Keith buys Indivior (INDV) shares worth $27,429
ca.investing.com
March 16, 2026 at 5:48 AM
Humphreys is a Director of Indivior, the company that makes sublocade
ca.investing.com/news/insider...
ca.investing.com/news/insider...
@ACCinhouse @ACCNatlCapital “Developing Your Deputy General Counsel Playbook” session on “Deputy General Counsel Playbook: Corporate Secretary Fundamentals” w/ Mayme Donohue, Partner, @HuntonAK LLP & Alice Givens, Company Secretary, Indivior Pharmaceuticals, Inc. #Integrity
October 2, 2026 at 2:48 PM
@ACCinhouse @ACCNatlCapital “Developing Your Deputy General Counsel Playbook” session on “Deputy General Counsel Playbook: Corporate Secretary Fundamentals” w/ Mayme Donohue, Partner, @HuntonAK LLP & Alice Givens, Company Secretary, Indivior Pharmaceuticals, Inc. #Integrity
• Mylan: $284,447,916
• Hikma: $95,818,293
• Amneal: $71,751,010
• Apotex: $63,682,369
• Indivior: $38,022,450
• Sun: $30,992,087
• Alvogen: $18,680,162
• Zydus: $14,859,220
These drugmakers callously profited off the rampant overprescribing and misuse of dangerously addictive opioids.
• Hikma: $95,818,293
• Amneal: $71,751,010
• Apotex: $63,682,369
• Indivior: $38,022,450
• Sun: $30,992,087
• Alvogen: $18,680,162
• Zydus: $14,859,220
These drugmakers callously profited off the rampant overprescribing and misuse of dangerously addictive opioids.
July 10, 2025 at 6:58 PM
• Mylan: $284,447,916
• Hikma: $95,818,293
• Amneal: $71,751,010
• Apotex: $63,682,369
• Indivior: $38,022,450
• Sun: $30,992,087
• Alvogen: $18,680,162
• Zydus: $14,859,220
These drugmakers callously profited off the rampant overprescribing and misuse of dangerously addictive opioids.
• Hikma: $95,818,293
• Amneal: $71,751,010
• Apotex: $63,682,369
• Indivior: $38,022,450
• Sun: $30,992,087
• Alvogen: $18,680,162
• Zydus: $14,859,220
These drugmakers callously profited off the rampant overprescribing and misuse of dangerously addictive opioids.
UK's Indivior to re-domicile to US after listing move reut.rs/4gQv7du
UK's Indivior to re-domicile to US after listing move
Indivior , said on Wednesday it plans to relocate its corporate domicile from the UK to the United States, establishing a new Delaware-based parent company, just months after the pharmaceutical firm moved its primary listing to New York.
reut.rs
October 1, 2025 at 1:40 PM
UK's Indivior to re-domicile to US after listing move reut.rs/4gQv7du
In which CBC attempts to both-sides forced abstinence but fails to disclose Keith Humphreys' position as a paid board member at Indivior, among the companies that stands to profit most from institutionalizing people who use drugs.
www.cbc.ca/news/health/...
www.cbc.ca/news/health/...
November 10, 2024 at 5:36 PM
In which CBC attempts to both-sides forced abstinence but fails to disclose Keith Humphreys' position as a paid board member at Indivior, among the companies that stands to profit most from institutionalizing people who use drugs.
www.cbc.ca/news/health/...
www.cbc.ca/news/health/...
Corporatism over lives.
"Of these options, Sublocade is the only medication with an exclusive patent still held by a pharmaceutical company. That company is Indivior, which has lobbied Correctional Service Canada on “the application of addiction treatments within federal prisons” in recent years."
"Of these options, Sublocade is the only medication with an exclusive patent still held by a pharmaceutical company. That company is Indivior, which has lobbied Correctional Service Canada on “the application of addiction treatments within federal prisons” in recent years."
NEW
Federal prisons are removing methadone and Suboxone opioid treatments, leaving only a patented once-per-month injection for prisoners.
A large group of experts is raising serious concerns about harms to prisoners––and the corporate motivations behind the move.
drugdatadecoded.ca/150-experts-...
Federal prisons are removing methadone and Suboxone opioid treatments, leaving only a patented once-per-month injection for prisoners.
A large group of experts is raising serious concerns about harms to prisoners––and the corporate motivations behind the move.
drugdatadecoded.ca/150-experts-...
150 experts demand Correctional Service Canada reverse "coercive" opioid treatment guidance
A new policy in federal prisons removes methadone and Suboxone opioid treatments, leaving only a patented once-per-month gel injection available to prisoners. A large group of experts is raising serio...
drugdatadecoded.ca
December 16, 2025 at 2:37 AM
Corporatism over lives.
"Of these options, Sublocade is the only medication with an exclusive patent still held by a pharmaceutical company. That company is Indivior, which has lobbied Correctional Service Canada on “the application of addiction treatments within federal prisons” in recent years."
"Of these options, Sublocade is the only medication with an exclusive patent still held by a pharmaceutical company. That company is Indivior, which has lobbied Correctional Service Canada on “the application of addiction treatments within federal prisons” in recent years."
A study authored by Indivior employees, based on Indivior data, finds that concerns about nalmefene-precipitated withdrawal appear unfounded.
Indivior Isn't Done With Opvee, the Overdose Antidote That's Not Narcan
A study authored by Indivior employees, based on Indivior data, finds that concerns about nalmefene-precipitated withdrawal appear unfounded.
filtermag.org
October 24, 2025 at 2:11 PM
A study authored by Indivior employees, based on Indivior data, finds that concerns about nalmefene-precipitated withdrawal appear unfounded.
@calgaryherald.com Stenography for Alberta govt facilitation of pharma interests isn’t journalism.
How about this: the chair of Alberta’s Recovery Advisory Panel was a board member & major investor in Indivior, pharma corp pushing drugs at the centre of this story.
calgaryherald.com/news/local-n...
How about this: the chair of Alberta’s Recovery Advisory Panel was a board member & major investor in Indivior, pharma corp pushing drugs at the centre of this story.
calgaryherald.com/news/local-n...
Top Alberta doctor touts once-a-month shot to counter OD brain damage
Brain injuries from subsequent overdoses aren’t different from those of dementia, said Dr. Nathaniel Day, looking to Sublocade for a fix.
calgaryherald.com
August 31, 2026 at 9:53 PM
@calgaryherald.com Stenography for Alberta govt facilitation of pharma interests isn’t journalism.
How about this: the chair of Alberta’s Recovery Advisory Panel was a board member & major investor in Indivior, pharma corp pushing drugs at the centre of this story.
calgaryherald.com/news/local-n...
How about this: the chair of Alberta’s Recovery Advisory Panel was a board member & major investor in Indivior, pharma corp pushing drugs at the centre of this story.
calgaryherald.com/news/local-n...
Humphreys is on the BoD of Indivior, which sells Sublocade & Suboxone - patented opioid replacement meds frequently pushed on people in residential treatment and prison settings.
Humphreys' thinktank was also commissioned by AB govt to attack harm reduction: drugdatadecoded.ca/laundering-b...
Humphreys' thinktank was also commissioned by AB govt to attack harm reduction: drugdatadecoded.ca/laundering-b...
June 16, 2025 at 4:50 PM
Humphreys is on the BoD of Indivior, which sells Sublocade & Suboxone - patented opioid replacement meds frequently pushed on people in residential treatment and prison settings.
Humphreys' thinktank was also commissioned by AB govt to attack harm reduction: drugdatadecoded.ca/laundering-b...
Humphreys' thinktank was also commissioned by AB govt to attack harm reduction: drugdatadecoded.ca/laundering-b...
you brokies ruined a good thing
sincerely,
indivior
sincerely,
indivior
September 5, 2025 at 11:55 PM
you brokies ruined a good thing
sincerely,
indivior
sincerely,
indivior
Lollll
May this move by Indivior be the nail in the coffin for MCAM, the very existence of which is an affront to the old gods and the new
May this move by Indivior be the nail in the coffin for MCAM, the very existence of which is an affront to the old gods and the new
September 5, 2025 at 11:41 PM
Lollll
May this move by Indivior be the nail in the coffin for MCAM, the very existence of which is an affront to the old gods and the new
May this move by Indivior be the nail in the coffin for MCAM, the very existence of which is an affront to the old gods and the new
camx har inte råd missa rev nyckeldrivare (brixadi). Bilden är att market share stabiliserats vs Indivior, vilket gör cons framåt ser sportigt ut
May 15, 2025 at 6:52 AM
camx har inte råd missa rev nyckeldrivare (brixadi). Bilden är att market share stabiliserats vs Indivior, vilket gör cons framåt ser sportigt ut
other UK reporting:
#SAFE.L Safestore good, but no outlook
#CNA.L Centrica beat + £500mn buyback
#INDV.L Indivior guidance light
#AAL.L Anglo American big loss on impairments
#HAS.L Hays in-line
#ITH.L Ithaca Energy top end of production range
#BEG.L, #ARBB.L Begbies Traynor, Arbuthnot in-line
#SAFE.L Safestore good, but no outlook
#CNA.L Centrica beat + £500mn buyback
#INDV.L Indivior guidance light
#AAL.L Anglo American big loss on impairments
#HAS.L Hays in-line
#ITH.L Ithaca Energy top end of production range
#BEG.L, #ARBB.L Begbies Traynor, Arbuthnot in-line
February 20, 2025 at 7:27 AM
Major news in opioid crisis world: Indivior will no longer promote its controversial overdose-reversal medication Opvee, following lagging sales and outcry from harm reduction groups that it unnecessarily sent OD victims into agonizing withdrawal
www.statnews.com/2025/09/30/n...
www.statnews.com/2025/09/30/n...
Indivior to stop marketing Opvee, controversial overdose-reversal medication
Exclusive: Indivior is halting Opvee promotion after a New York settlement. Critics say the overdose drug is overpriced, risky, and no safer than widely used naloxone.
www.statnews.com
September 30, 2025 at 2:02 PM
Major news in opioid crisis world: Indivior will no longer promote its controversial overdose-reversal medication Opvee, following lagging sales and outcry from harm reduction groups that it unnecessarily sent OD victims into agonizing withdrawal
www.statnews.com/2025/09/30/n...
www.statnews.com/2025/09/30/n...
Story updated with more context, including studies showing terrible retention of Sublocade patients.
H/t @kwardvancouver.bsky.social for reminding me Keith Humphries is on the Indivior board, which continues to seem impossibly blatant.
H/t @kwardvancouver.bsky.social for reminding me Keith Humphries is on the Indivior board, which continues to seem impossibly blatant.
NEW
Federal prisons are removing methadone and Suboxone opioid treatments, leaving only a patented once-per-month injection for prisoners.
A large group of experts is raising serious concerns about harms to prisoners––and the corporate motivations behind the move.
drugdatadecoded.ca/150-experts-...
Federal prisons are removing methadone and Suboxone opioid treatments, leaving only a patented once-per-month injection for prisoners.
A large group of experts is raising serious concerns about harms to prisoners––and the corporate motivations behind the move.
drugdatadecoded.ca/150-experts-...
150 experts demand Correctional Service Canada reverse "coercive" opioid treatment guidance
A new policy in federal prisons removes methadone and Suboxone opioid treatments, leaving only a patented once-per-month gel injection available to prisoners. A large group of experts is raising serio...
drugdatadecoded.ca
December 16, 2025 at 4:55 PM
Story updated with more context, including studies showing terrible retention of Sublocade patients.
H/t @kwardvancouver.bsky.social for reminding me Keith Humphries is on the Indivior board, which continues to seem impossibly blatant.
H/t @kwardvancouver.bsky.social for reminding me Keith Humphries is on the Indivior board, which continues to seem impossibly blatant.
simply no mention that Keith Humpreys is on the board of Indivior...the company with a patent and contracts with local health authorities on the medication under review to be used more often under forced treatment expansion. ok then
June 16, 2025 at 2:50 PM
simply no mention that Keith Humpreys is on the board of Indivior...the company with a patent and contracts with local health authorities on the medication under review to be used more often under forced treatment expansion. ok then
Addex has reclaimed its full GABAB PAM portfolio from Indivior as the UK firm rationalises R&D. The Swiss biotech now holds global rights to a franchise it originally discovered.
Addex regains global GABAB PAM rights after Indivior R&D pullback
Addex Therapeutics has reclaimed its full GABAB positive allosteric modulator portfolio from Indivior, citing the UK firm's R&D rationalisation ahead of a planned
biotech.disruptsmedia.com
September 28, 2026 at 2:45 PM
Addex has reclaimed its full GABAB PAM portfolio from Indivior as the UK firm rationalises R&D. The Swiss biotech now holds global rights to a franchise it originally discovered.
"Indivior has not taken this action due to safety or efficacy issues,” the company wrote in a letter reviewed by Filter. “Rather, the decision was based on business reasons and shifting our focus to other parts of our business.”
Opvee, High-Profile Overdose Antidote No One Used, Discontinues Marketing
In a letter reviewed by Filter, Indivior said "business reasons," not an AG investigation, caused it to stop promoting the nalmefene product.
filtermag.org
October 1, 2025 at 2:47 PM
"Indivior has not taken this action due to safety or efficacy issues,” the company wrote in a letter reviewed by Filter. “Rather, the decision was based on business reasons and shifting our focus to other parts of our business.”
